Cogent Biosciences announced preclinical data presentations at the 2026 AACR Annual Meeting for two pipeline programs: CGT1263, a pan-KRAS(ON) inhibitor showing >500x selectivity over HRAS/NRAS with potential to reduce skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor demonstrating synergistic activity with HER2 ADCs. The company expects to submit an IND for CGT1263 later in 2026 and continues Phase 1 studies for CGT4255.

RTW Investments made a significant $116 million purchase of Cogent Biosciences shares in Q4, increasing its stake to 2.7% of AUM. The move signals confidence in the biotech company's lead drug candidate (CGT9486) and upcoming FDA decision timeline in late 2026. Cogent's stock has surged 360% over the past year, and the company has $900 million in cash runway through 2028.

Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.

Cogent Biosciences stock surged 5.24% after the FDA accepted its New Drug Application for bezuclastinib, a treatment for Non-Advanced Systemic Mastocytosis. The FDA decision is expected by December 30, 2026, with no advisory committee meeting planned. The company also plans to submit additional NDAs for GIST and Advanced Systemic Mastocytosis treatments in 2026.

Cogent Biosciences announced additional clinical results from the SUMMIT trial showing bezuclastinib achieved a mean TSS reduction of -32.0 points at 48 weeks, with 99% of patients achieving >50% reduction in serum tryptase and 83% achieving normalization. The data demonstrates consistent symptomatic improvements across multiple organ systems and evidence of disease modification in NonAdvanced Systemic Mastocytosis patients. The company's NDA for bezuclastinib in NonAdvSM was submitted in December 2025, with an APEX NDA submission for advanced SM expected in 1H 2026.

Cogent Biosciences announced multiple poster presentations highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis patients at the 2026 AAAAI Annual Meeting in Philadelphia. The company previously submitted a New Drug Application to the FDA in December 2025 based on positive clinical data, following the drug's Breakthrough Therapy Designation.

The FDA granted Breakthrough Therapy Designation to Cogent Biosciences' bezuclastinib combined with sunitinib for gastrointestinal stromal tumors (GIST). The PEAK trial showed a 50% reduction in disease progression risk compared to sunitinib alone, with median PFS of 16.5 months versus 9.2 months. The combination was well-tolerated with no new safety concerns. Cogent expects to complete its NDA submission in April 2026 and initiate a Phase 2 trial for first-line GIST patients in mid-2026.

Cogent Biosciences announced that CEO Andrew Robbins will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is developing precision therapies for genetically defined diseases, with bezuclastinib as its most advanced program for systemic mastocytosis and gastrointestinal stromal tumors. Recent positive trial results showed a 57-80% objective response rate in advanced systemic mastocytosis patients.

Cogent Biosciences announced positive clinical trial results for bezuclastinib, demonstrating significant improvements in symptoms and disease markers for patients with nonadvanced systemic mastocytosis, with plans to submit a New Drug Application in December 2025.

Cogent Biosciences will participate in the Jefferies Global Healthcare Conference in London, presenting a live webcast about their precision therapies for genetically defined diseases, with a focus on their lead clinical program bezuclastinib.

Cogent Biosciences priced a public offering of 9,677,420 common stock shares at $31.00 per share and $200 million in convertible senior notes due 2031, expecting net proceeds of approximately $475.3 million to fund development activities and repay existing loans.

Cogent Biosciences will present data on bezuclastinib for NonAdvanced Systemic Mastocytosis at the ASH annual meeting, highlighting potential disease modification and introducing a new JAK2 V617F mutant-selective inhibitor program.